Skip to main content

Fujifilm's COVID-19 drug enters testing in US; will be free to 20 countries

Fujifilm's COVID-19 drug gets clinical tests in US; will be offered free to 20 countries
(Image credit: Fujifilm Holdings Corporation)

Clinical testing for Fujifilm's COVID-19 treatment drug, Avigan, has officially commenced in the United States, following the testing that began in Japan at the end of March. Further, the Japanese government has pledged that the drug will be made freely available to 20 countries to aid in the fight against the coronavirus pandemic.

Fujifilm announced today the initiation of phase II clinical trials in the US to evaluate the safety and efficacy of Avigan (which also goes by the generic name favipiravir). The trial will take place in collaboration with Brigham and Women’s Hospital, Massachusetts General Hospital, and the University of Massachusetts Medical School, and will involve some 50 patients infected with COVID-19.

"Avigan, approved in Japan for manufacture and sale as an influenza antiviral drug, selectively inhibits RNA polymerase necessary for influenza virus replication," notes the announcement from Fujifilm (opens in new tab)

"Due to this mechanism of action, it is expected that Avigan may potentially have an antiviral effect on the new coronavirus, because like influenza viruses, coronaviruses are single-stranded RNA viruses that also depend on viral RNA polymerase."

At the same time, the Japanese government will boost its stockpile of the drug, with Prime Minister Shinzo Abe pledging to triple the nation's supply in order to treat two million infected people.

“We will work with interested countries to expand clinical research on Avigan internationally,” Foreign Minister Toshimitsu Motegi told press on Tuesday. 

According to Japan Times (opens in new tab), "the 20 countries receiving the drug, which is currently undergoing clinical tests, include Bulgaria, the Czech Republic, Indonesia, Iran, Myanmar, Saudi Arabia and Turkey, with an additional 30 countries showing interest."

The report notes that Japan is working directly with the United Nations, and will provide the UN Office for Project Services with a $1 million grant to buy and distribute the drug.

Read more: 

Fujifilm has developed new coronavirus test that produces results in just 2 hours (opens in new tab)
Fujifilm's medical division successful in treating COVID-19 (opens in new tab)
The best Fujifilm cameras (opens in new tab) in 2020: from X-mount mirrorless to GFX medium format

Thank you for reading 5 articles this month* Join now for unlimited access

Enjoy your first month for just £1 / $1 / €1

*Read 5 free articles per month without a subscription

Join now for unlimited access

Try first month for just £1 / $1 / €1

James Artaius
James Artaius

The editor of Digital Camera World, James has 21 years experience as a magazine and web journalist and started working in the photographic industry in 2014 (as an assistant to Damian McGillicuddy, who succeeded David Bailey as Principal Photographer for Olympus). In this time he shot for clients as diverse as Aston Martin Racing, Elinchrom and L'Oréal, in addition to shooting campaigns and product testing for Olympus, and providing training for professionals. This has led him to being a go-to expert for camera and lens reviews, photographic and lighting tutorials, as well as industry analysis, news and rumors for publications such as Digital Camera Magazine (opens in new tab)PhotoPlus: The Canon Magazine (opens in new tab)N-Photo: The Nikon Magazine (opens in new tab)Digital Photographer (opens in new tab) and Professional Imagemaker, as well as hosting workshops and demonstrations at The Photography Show (opens in new tab). An Olympus and Canon shooter, he has a wealth of knowledge on cameras of all makes – and a fondness for vintage lenses and instant cameras.